title: Roferon (rIFN-alpha 2a) is more immunogenic than intron A (rIFN-alpha 2b) in patients with chronic myelogenous leukemia.
authors: Department of Immunology and Transfusion Medicine, Medical School of Hannover, Germany.
authors: P
authors: P
authors: Von Wussow
authors: R
authors: R
authors: Hehlmann
authors: T
authors: T
authors: Hochhaus
authors: D
authors: D
authors: Jakschies
authors: K U
authors: KU
authors: Nolte
authors: O
authors: O
authors: Prümmer
authors: H
authors: H
authors: Ansari
authors: J
authors: J
authors: Hasford
authors: H
authors: H
authors: Heimpel
authors: H
authors: H
authors: Deicher
mesh_terms: D000917:Antibody Formation; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D011994:Recombinant Proteins
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins